WO1999064599A1 - Cyclin-dependent kinase inhibitors as plant growth regulators - Google Patents
Cyclin-dependent kinase inhibitors as plant growth regulators Download PDFInfo
- Publication number
- WO1999064599A1 WO1999064599A1 PCT/CA1999/000532 CA9900532W WO9964599A1 WO 1999064599 A1 WO1999064599 A1 WO 1999064599A1 CA 9900532 W CA9900532 W CA 9900532W WO 9964599 A1 WO9964599 A1 WO 9964599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant
- cyclin
- nucleic acid
- dependent kinase
- kinase inhibitor
- Prior art date
Links
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title claims abstract description 115
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title claims abstract description 84
- 239000005648 plant growth regulator Substances 0.000 title description 2
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 66
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 66
- 238000011161 development Methods 0.000 claims abstract description 61
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 claims abstract description 54
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 claims abstract description 51
- 230000009261 transgenic effect Effects 0.000 claims abstract description 48
- 230000012010 growth Effects 0.000 claims abstract description 32
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims abstract description 29
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 26
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims abstract description 17
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims abstract description 17
- 230000000295 complement effect Effects 0.000 claims abstract description 13
- 230000001131 transforming effect Effects 0.000 claims abstract description 8
- 230000001172 regenerating effect Effects 0.000 claims abstract description 4
- 238000012258 culturing Methods 0.000 claims abstract 3
- 241000196324 Embryophyta Species 0.000 claims description 264
- 230000014509 gene expression Effects 0.000 claims description 72
- 230000018109 developmental process Effects 0.000 claims description 54
- 241000219198 Brassica Species 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 235000011331 Brassica Nutrition 0.000 claims description 5
- 230000011712 cell development Effects 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 241000219193 Brassicaceae Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 86
- 210000000056 organ Anatomy 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 69
- 210000001519 tissue Anatomy 0.000 description 47
- 101150012716 CDK1 gene Proteins 0.000 description 42
- 230000000694 effects Effects 0.000 description 31
- 239000002299 complementary DNA Substances 0.000 description 30
- 230000003993 interaction Effects 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 29
- 108050006400 Cyclin Proteins 0.000 description 22
- 241000219194 Arabidopsis Species 0.000 description 21
- 108091000080 Phosphotransferase Proteins 0.000 description 19
- 102000020233 phosphotransferase Human genes 0.000 description 19
- 230000009466 transformation Effects 0.000 description 18
- 238000012217 deletion Methods 0.000 description 17
- 230000037430 deletion Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 240000002791 Brassica napus Species 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 12
- 102000016736 Cyclin Human genes 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108091007914 CDKs Proteins 0.000 description 11
- 238000010396 two-hybrid screening Methods 0.000 description 11
- 238000001086 yeast two-hybrid system Methods 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 101710112752 Cytotoxin Proteins 0.000 description 9
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 9
- 238000009739 binding Methods 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000008121 plant development Effects 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 244000300310 Chenopodium rubrum Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 239000002619 cytotoxin Substances 0.000 description 6
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 206010021929 Infertility male Diseases 0.000 description 5
- 208000007466 Male Infertility Diseases 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 208000021267 infertility disease Diseases 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 230000008635 plant growth Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000219195 Arabidopsis thaliana Species 0.000 description 4
- 101100273247 Arabidopsis thaliana KRP1 gene Proteins 0.000 description 4
- 101100288232 Arabidopsis thaliana KRP2 gene Proteins 0.000 description 4
- 244000060924 Brassica campestris Species 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102100028233 Coronin-1A Human genes 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
- 101000913761 Homo sapiens Serine/threonine-protein kinase ICK Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- 102100026621 Serine/threonine-protein kinase ICK Human genes 0.000 description 4
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000003158 yeast two-hybrid assay Methods 0.000 description 4
- 241000589158 Agrobacterium Species 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 244000257790 Brassica carinata Species 0.000 description 3
- 101150047144 CDC28 gene Proteins 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000219312 Chenopodium Species 0.000 description 3
- 235000009332 Chenopodium rubrum Nutrition 0.000 description 3
- 108010058545 Cyclin D3 Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 102400001093 PAK-2p27 Human genes 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 230000007152 anther development Effects 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000006870 ms-medium Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001902 propagating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000022983 regulation of cell cycle Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940027257 timentin Drugs 0.000 description 3
- KUWPCJHYPSUOFW-SCWFEDMQSA-N (2r,3r,4s,5r)-2-(hydroxymethyl)-6-(2-nitrophenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)OC1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-SCWFEDMQSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 2
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 2
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108010001515 Galectin 4 Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 108700021031 cdc Genes Proteins 0.000 description 2
- 101150069072 cdc25 gene Proteins 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000003348 filter assay Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229930195732 phytohormone Natural products 0.000 description 2
- 230000010152 pollination Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012250 transgenic expression Methods 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- JLIDBLDQVAYHNE-LXGGSRJLSA-N 2-cis-abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\C1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-LXGGSRJLSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100288238 Arabidopsis thaliana KRP5 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000011292 Brassica rapa Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000930171 Caryophyllidae Species 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101150033981 TUBA4 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000009418 agronomic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- -1 cdc2a Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000021759 endosperm development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000012135 ice-cold extraction buffer Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000020673 lateral root development Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000002596 lutein cell Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000442 meristematic effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000023409 microsporogenesis Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 230000008119 pollen development Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000023276 regulation of development, heterochronic Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000008128 stamen development Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Definitions
- the invention relates to the modification of growth and development of plants through transgenic sense or anti-sense expression of cyclin-dependent kinase inhibitor genes.
- CDK cyclin-dependent protein kinase
- CDKs in yeast.
- Cdc2 p34 cdc2 , or
- CDK1 was identified in fission yeast Schizosaccharomyces pombe (Hindley and Phear, 1984) and a Cdc2 homolog called CDC28 was identified in budding yeast Saccharomyces cerevisiae (Lorincz and Reed, 1984).
- Cdc2 (or CDC28) kinase appears to be solely responsible for regulating the progression of the cell cycle.
- Cdc2a and Cdc2b In Arabidopsls thaliana, at least two Cdc2 homologues, Cdc2a and Cdc2b (Ferreira et al., 1991; Hirahama et al., 1991) and as many as twelve cyclins belonging to three groups (Renaudin et al., 1996) have so far been documented. Of the two Cdc2 homologues in A.
- thaliana, Cdc2a resembles more closely Cdc2 homologues from other species because it has a conserved PSTAIRE motif and is able to genetically complement yeast cdc2 or CDC28 mutants (Ferreira et al., 1991; Hirahama et al, 1991), indicating some functional homology of A. thaliana Cdc2a with the yeast Cdc2 kinase. Expression analyses showed that A.
- thaliana cdc2a expression was correlated with the "competence" of a cell to divide and preceded the re-entry of differentiated cells into the cell division cycle (Martinez et al, 1992; Hemerly et al., 1993), and expression of a dominant negative cdc2a mutant resulted in cell cycle arrest (Hemerly et al., 1995).
- A. thaliana Cdc2b is atypical in that it has a PPTALRE motif in place of the PSTAIRE motif.
- cdc2b is also expressed in dividing plant cells. While cdc2a is expressed constitutively throughout the cell cycle, cdc2b is reportedly expressed preferably in S and G2 phases (Segers et al., 1996).
- CDK inhibitors A new aspect of regulating CDK activity was discovered with the identification of CDK inhibitors (see reviews by Pines, 1995; Sherr and Roberts, 1995; Harper and Ellege, 1996). These small molecular weight proteins are understood to bind stoichiometrically to negatively regulate the activity of CDKs. It has been suggested that these inhibitors may be involved in animal development and cancer, in addition to their role in cell cycle regulation (Harper and Elledge, 1996). A plant CDK inhibitor activity was observed and was suggested to be involved in endosperm development in maize (Grafi and Larkins, 1995). The activity of CDK inhibitors has been studied in animals. Transgenic mice have been generated lacking p21, p27 and p57 CDK inhibitor genes.
- the p21 knockout mice are reported to develop normally but are deficient in Gl checkpoint control, such as cell cycle arrest in response to DNA damage (Deng et al, 1995).
- Analysis of p27 knockout mice from three independent studies show that transgenic mice lacking p27 display larger body size than control mice (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996).
- the enhanced growth is reportedly due to an increase in cell number (Kiyokawa et al., 1996) and is gene dose-dependent (Fero et al., 1996).
- none of p21 or p57 knockout display enhanced growth.
- the transgenic mice lacking p57 show a range of developmental defects such as defective abdominal muscles, cleft palate and renal medullary dysplasia (Yan et al., 1997; Zhang et al., 1997).
- a few developmental defects were observed in p27-/- mice. They include impaired ovarian follicles (thus female sterility), impaired luteal cell differentiation and a disordered estrus cycle. These results reflect a disturbance of the hypothalamic- pituitary-ovarian axis.
- transgenic mice lacking p21 appear to develop normally at both gross anatomic and histologic levels (Deng et al., 1995).
- an increase in apoptosis is observed in mice lacking p57.
- the CDK inhibitor p27 was over- expressed in mouse hepatocytes (Wu et al., 1996), resulting in a general a decrease in overall number of adult hepatocytes which result in aberrant tissue organization, body growth and mortality.
- Plants also have an inherent ability to incorporate additional growth into normal developmental patterns, as is illustrated by a study showing that ectopic expression of a mitotic cyclin driven by the cdc2a promoter resulted in a larger but normal root system (Doerner et al, 1996). However, relatively little is known about the connections of the regulatory genes controlling cell division patterns to the cell cycle regulators such as the CDKs and the cyclins in plants (Meyerowitz, 1997).
- a heterologous yeast cdc25 a mitotic inducer gene, was introduced into tobacco plants under the control of a constitutive CaMN 35s promoter (Bell et al., 1993).
- Transgenic tobacco plants showed abnormal leaves (lengthened and twisted lamina, pocketed interveinal regions), abnormal flowers, and also precocious flowering.
- Analysis of cell size in the root meristem revealed that transgenic plants expressing the yeast cdc25 had much smaller cells (Bell et al, 1993).
- the wild type cdc2a gene and variants of dominant negative mutations under the control of CaMV 35s promoter have been used to transform tobacco and Arabidopsis plants (Hemerly et al., 1995). Constitutive expression of wild-type and mutant Cdc2a did not significantly alter the development of the transgenic plants. For the dominant negative Cdc2a mutant, it was not possible to regenerate Arabidopsis plants. Some tobacco plants expressing this construct were obtained and they had considerably fewer but much larger cells. These cells, however, underwent normal differentiation. Morphogenesis, histogenesis and developmental timing were unaffected (Hemerly et al., 1995).
- ICK1 cyclin-dependent kinase inhibitor gene ICK1 from a plant.
- ICK1 is different in sequence, structure and inhibitory properties from known mammalian CDK inhibitors. It has been shown that recombinant protein produced from this gene in bacteria is able to inhibit plant Cdc2-like kinase activity in vitro (Wang et al, 1997).
- Cytotoxin genes i.e. genes encoding a protein which will cause cell death, have been tested in transgenic plants for genetic ablation of specific cells or cell lines during development, including R ⁇ ase (Mariani et al., 1990), DTT (diphitheria toxin) chain A (Thorsness et al., 1991; Czako et al, 1992), Exotoxin A (Koning et al., 1992) and ribosomal inhibitor proteins (United States Patent No. 5,723,765 issued 3 March 1998 to Oliver et al.).
- cytotoxin genes i.e. genes encoding a protein which will cause cell death
- the action of the cytotoxin may not be specific and may result in non-specific destruction of plant cells. This effect may be the result of diffusion of the cytotoxin, or of non-specific expression of the cytotoxin gene in non-target tissues.
- Non-specific low-level expression of the cytotoxin may be a difficult problem to overcome, since most tissue-specific promoters have some levels of expression in other tissues in addition to a high level of expression in a particular tissue.
- Expression of a potent cytotoxin gene even at a low concentration may have a negative impact on growth and development in non-target tissues.
- the presence of cytotoxic proteins of transgenic origin may also have a negative effect on the marketability of an edible plant, or plant product, even if the cytotoxin is demonstrably benign to consumers.
- the invention provides methods of modifying plant or plant cell development using CDK inhibitors.
- the word 'development' encompasses a wide variety of biological process, including growth, morphogenesis, multiplication, enlargement, differentiation or maturation of a cell.
- the methods of the invention involve transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, or an anti-sense construct complementary to such a nucleic acid, to produce a transformed plant cell; and, growing the transformed plant cell, or progeny of the transformed plant cell, under conditions wherein the cyclin-dependent kinase inhibitor polypeptide, or the anti-sense construct, is expressed in the transformed plant cell or in the progeny of the transformed plant cell.
- the growing of the transformed plant cell or progeny of the transformed plant cell may be carried out to produce a transformed plant, and the cyclin- dependent kinase inhibitor polypeptide, or anti-sense construct, may be expressed to modify the development of the transformed plant or progeny of the transformed plant.
- the invention provides methods for using CDK inhibitor genes to modify the growth and development of plant cells and organs.
- the invention provides a method of modifying the development of a plant comprising (i.e. having or including, but not limited to) transforming a plant cell with a nucleic acid encoding a cyclin- dependent kinase inhibitor to produce a transformed plant cell.
- a plant may then be regenerated from the transformed plant cell under conditions wherein the cyclin-dependent kinase inhibitor is expressed during regeneration or growth of the plant to modify the development of the plant.
- the nucleic acid encoding the cyclin-dependent kinase inhibitor may be homologous to ICKl, or may be ICKl, respectively encoding a cyclin-dependent kinase inhibitor homologous to ICKl or ICKl itself.
- the plant may be A. thaliana, or a member of the Brassica genus, or a canola variety.
- the nucleic acid encoding the cyclin-dependent kinase inhibitor may be operably linked to a tissue-specific promoter, such as AP3 or a promoter homologous to AP3.
- a tissue-specific promoter such as AP3 or a promoter homologous to AP3.
- the tissue-specific promoter may mediate expression of the nucleic acid encoding the cyclin- dependent kinase inhibitor in petal and/or stamen primordia, and the development of the plant may be modified so that the plant has altered petals and/or is male sterile.
- transgenic plants comprising (i.e. having or including, but not limited to) an expressible heterologous nucleic acid encoding a cyclin- dependent kinase inhibitor, wherein the heterologous nucleic acid is introduced into the plant, or an ancestor of the plant, by the foregoing method.
- the plants may comprise a nucleic acid encoding a cyclin-dependent kinase inhibitor, and the plant cells may be transformed with an anti-sense nucleic acid complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor, to produce a transformed plant cell.
- Plants of the invention may have a recombinant genome and the heterologous nucleic acid may be integrated into the recombinant genome.
- the invention encompasses plant tissues, such as seeds, comprising a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor, or an anti-sense construct, that is expressed during the development of a plant from the tissue to modify the development of the plant.
- the invention also provides methods of identifying nucleic acids that encode cyclin-dependent kinase inhibitors, such as nucleic acids homologous to ICKl, that are active in plants to modify the growth or development of the plants.
- Figure 1 shows cDNA (Wang et al., 1997) and genomic sequences of ICKl, wherein: (A) shows the genomic organization ICKl. Open bars represent exons and filled bars represent introns; (B) shows features of the cDNA sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2).
- Figure 2 shows the alignment of ICKl CDNA sequence (SEQ ID NO: 3) with ICKlb (SEQ ID NO: 4) and ICKc (SEQ ID NO: 5).
- Figure 3 shows the cDNA sequence of ICK2 (SEQ ID NO: 6).
- Figure 4 shows the cDNA sequence of ICN2 (SEQ ID NO: 7).
- Figure 5 shows the cDNA sequence of ICN6 (SEQ ID NO: 8).
- Figure 6 shows the cDNA sequence of ICN7 (SEQ ID NO: 9); The nucleotide sequence of Chenopodium rubrum CDKIl (GenBank AJ002173, SEQ ID NO. 15); and, The amino acid sequence of Chenopodium rubrum CDKIl (SEQ ID NO. 16).
- Figure 7 shows the alignment of deduced amino acid sequences of ICKl (SEQ ID NO: 10), ICK 2 (SEQ ID NO: 11), 7CN2 (SEQ ID NO: 12), 7CN6 ⁇ (SEQ ID NO: 13), and ICN7 (SEQ ID NO: 14), and a resultant consensus sequence.
- Figure 8 shows deletion mapping in the yeast two-hybrid system of functional regions of ICKl involved in interactions with Cdc2a and CycD3 (cyclin 53) in the two-hybrid system.
- the invention provides methods of modifying plant or plant cell development.
- the word 'development' encompasses a wide variety of biological process, including growth, morphogenesis, multiplication, enlargement, differentiation or maturation of a cell or plant.
- the methods of the invention involve transforming a plant cell with a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, or an anti-sense construct complementary to such a nucleic acid, to produce a transformed plant cell; and, growing the transformed plant cell, or progeny of the transformed plant cell, under conditions wherein the cyclin-dependent kinase inhibitor polypeptide, or the anti-sense construct, is expressed in the transformed plant cell or in the progeny of the transformed plant cell.
- a 'CDK inhibitor polypeptide' is any polypeptide capable of inhibiting a CDK, preferably a CDK active during development of a plant or plant cell.
- the growing of the transformed plant cell or progeny of the transformed plant cell may be carried out to produce a transformed plant, such as by regenerating a plant from a transformed culture or by propagating or growing whole plants from transformed plant parts.
- the cyclin-dependent kinase inhibitor polypeptide, or anti-sense construct may be expressed to modify the development of the transformed plant or progeny of the transformed plant.
- 'progeny' with reference to a plant, includes progeny produced sexually or asexually (for example by tissue culture-based propagation).
- the term 'growing' with reference to the transformed cells or plants includes all methods for growing and propagating cells or plants, such as tissue culture or horticultural means of propagating plants or plant parts.
- promoter means a sequence sufficient to direct transcription of a gene when the promoter is operably linked to the gene.
- the promoter is accordingly the portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription.
- Promoter sequences are commonly, but not universally, located in the 5' non-coding regions of a gene.
- a promoter and a gene are "operably linked” when such sequences are functionally connected so as to permit gene expression mediated by the promoter.
- operably linked accordingly indicates that DNA segments are arranged so that they function in concert for their intended purposes, such as initiating transcription in the promoter to proceed through the coding segment of a gene to a terminator portion of the gene.
- Gene expression may occur in some instances when appropriate molecules (such as transcriptional activator proteins) are bound to the promoter. Expression is the process of conversion of the information of a coding sequence of a gene into niRNA by transcription and subsequently into polypeptide (protein) by translation, as a result of which the protein is said to be expressed.
- a gene or nucleic acid is "expressible” if it is capable of expression under appropriate conditions in a particular host cell.
- promoters may be used that provide for preferential gene expression within a specific organ or tissue, or during a specific period of development.
- promoters may be used that are specific for leaf (Dunsmuir, et al Nucleic Acids Res, (1983) 11 :4177-4183), root tips (Pokalsky, et al Nucleic Acids Res, (1989) 17:4661-4673), fruit (Peat, et al Plant Mol. Biol, (1989) 13:639-651; United States Patent No. 4,943,674 issued 24 July, 1990; International Patent Publication WO-A 8 809 334; United States Patent No.
- Promoters may be identified from genes which have a differential pattern of expression in a specific tissue by screening a tissue of interest, for example, using methods described in United States Patent No. 4,943,674 and European Patent Application EP-A 0255378.
- the disclosure herein includes examples of this aspect of the invention, showing that plant tissues and organs can be modified by transgenic expression of a plant CDK inhibitor.
- Non-dividing plant cells may tolerate low level expression of CDK inhibitors, such as ICKl, in non-targeted tissues.
- CDK inhibitors such as ICKl
- the invention may be practiced in some embodiments using tissue specific promoters operably linked to CDK inhibitor encoding sequences, even when the promoter mediates a tolerable basal level of expression in other tissues.
- nucleic acid or amino acid sequences that are homologous to other sequences.
- an amino acid or nucleic acid sequence is "homologous" to another sequence if the two sequences are substantially identical and the functional activity of the sequences is conserved (for example, both sequences function as or encode a cyclin-dependent kinase inhibitor; as used herein, sequence conservation or identity does not infer evolutionary relatedness).
- Nucleic acid sequences may also be homologous if they encode substantially identical amino acid sequences, even if the nucleic acid sequences are not themselves substantially identical, for example as a result of the degeneracy of the genetic code.
- sequence identity may for example be at least 75%, at least 90% or at least 95%.
- Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, such as the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci.
- Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al. (1990), J. Mol. Biol. 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at http://www.ncbi.nlm.nih.gov/).
- the BLAST algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive- valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold.
- Initial neighborhood word hits act as seeds for initiating searches to find longer HSPs.
- the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction is halted when the following parameters are met: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
- the BLAST program may use as defaults a word length (W) of 11 , the BLOSUM62 scoring matrix (Henikoff and Henikoff
- nucleotide or amino acid sequences are considered substantially identical if the smallest sum probability in a comparison of the test sequences is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
- hybridize to each other under moderately stringent, or preferably stringent, conditions Hybridization to filter-bound sequences under moderately stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65 °C, and washing in 0.2 x SSC/0.1% SDS at 42 °C (see Ausubel, et al. (eds), 1989, Current Protocols in Molecular Biology, Vol. 1, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3).
- hybridization to filter-bound sequences under stringent conditions may, for example, be performed in 0.5 M NaHPO 4 , 7% SDS, 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (see Ausubel, et al. (eds), 1989, supra).
- Hybridization conditions may be modified in accordance with known methods depending on the sequence of interest (see Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology — Hybridization with Nucleic Acid
- stringent conditions are selected to be about 5°C lower than the thermal melting point for the specific sequence at a defined ionic strength and pH.
- an alternative indication that two amino acid sequences are substantially identical is that one peptide is specifically immunologically reactive with antibodies that are also specifically immunoreactive against the other peptide.
- Antibodies are specifically immunoreactive to a peptide if the antibodies bind preferentially to the peptide and do not bind in a significant amount to other proteins present in the sample, so that the preferential binding of the antibody to the peptide is detectable in an immunoassay and distinguishable from non-specific binding to other peptides.
- immunoassay formats such as solid-phase ELISA immunoassays for selecting monoclonal antibodies specifically immunoreactive with a protein (see Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York).
- the cyclin-dependent kinase inhibitors of the present invention may include non-naturally occurring sequences, such as functionally active fragments of naturally occurring sequences.
- fragments of ICKl, or amino acid sequences homologous to those fragments, that have cyclin-dependent kinase inhibitory activity may be used in some embodiments of the invention.
- the invention provides methods for identifying such fragments, for example by deletion mapping of active cyclin-dependent kinase inhibitors.
- cyclin-dependent kinase inhibitor therefore includes any polypeptide capable of functioning to inhibit a cyclin- dependent kinase and may be used to modify the growth or development of the plant, the invention similarly encompasses nucleic acid sequences encoding such polypeptides.
- heterologous refers to molecules or portions of molecules, such as DNA sequences, that are artificially introduced into a particular host cell.
- Heterologous DNA sequences may for example be introduced into a host cell by transformation.
- Such heterologous molecules may include sequences derived from the host cell.
- Heterologous DNA sequences may become integrated into the host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination events.
- the specificity of a CDK inhibitor may be assayed in vivo.
- the ICKl coding sequence was fused to a known promoter which directed gene expression in pollen but not in stamen primordia.
- the transformants are normal and fertile. This result indicates that in specific embodiments of the invention, expression of ICKl is not generally toxic to tissues other than the target tissue.
- Phenotypes may be obtained, for example with the exemplified AP3-ICK1 transformants, that are due to specific action of the CDK inhibitor, such as ICKl protein, on cell division.
- the CDK inhibitor such as ICKl
- the CDK inhibitor such as ICKl
- the CDK inhibitor action may be made to be specific only to certain cells, avoiding the nonspecific destruction of plant cells. This specificity may be achieved partly because non- dividing plant cells in non-targeted tissues may have better tolerance of low level expression of a CDK inhibitor than a cytotoxin.
- tissue specific promoters for expressing CDK inhibitors when such promoters still have a tolerable basal level of expression in other tissues.
- tissue-specific promoters have some levels of expression in other tissues in addition to a high level of expression in a particular tissue.
- expression of a potent cytotoxic gene in one tissue can have a negative impact on growth and development in other tissues.
- the down-regulation of CDK inhibitors may be used to enhance growth during plant development.
- Such growth enhancement may be tissue-specific.
- anti-sense oligonucleotides may be expressed to down-regulate expression of CDK inhibitors.
- the expression of such anti-sense constructs may be made to be tissue-specific by operably linking anti-sense encoding sequences to tissue-specific promoters.
- Anti-sense oligonucleotides, including anti-sense RNA molecules and anti-sense DNA molecules act to block the translation of mRNA by binding to targeted mRNA and inhibiting protein translation from the bound mRNA.
- anti-sense oligonucleotides complementary to regions of a DNA sequence encoding a CDK inhibitor may be expressed in transformed plant cells during development to down-regulate the CDK inhibitor.
- Alternative methods of down-regulating CDK inhibitor gene expression may include the use of ribozymes or other enzymatic RNA molecules (such as hammerhead RNA structures) that are capable of catalyzing the cleavage of RNA (as disclosed in U.S. Patent Nos. 4,987,071 and 5,591,610).
- the mechanism of ribozyme action generally involves sequence specific hybridization of the ribozyme molecule to complementary target RNA , followed by endonucleolytic cleavage.
- Arabidopsis thaliana "Columbia” may be used as a convenient model system for identifying CDK inhibitors that are useful in various embodiments of the present invention.
- Arabidopsis plants are generally grown in pots placed in growth chambers (20°C 16h/8h of day/night). Other plants may also of course be used in various embodiments of the invention in accordance with known growth and transformation techniques.
- Yeast two-hybrid cloning and assay techniques may be used to identify and assess CDK inhibitors useful in the present invention.
- a cDNA library may be made using poly (A) mRNA isolated from whole plants at different stages of development and cloned in a suitable vector, such as Gal4 TA- (transcription-activation domain) pPC86 (Chevray and Nathans, 1992; available from GIBCO/BRL Life Technologies) or pBI771- a modified pPC86 (Koholmi et al., 1997).
- the cDNA of the gene (such as cdc2a, cyclin 52 and cyclin 53) to be used for screening the library may be cloned in a suitable vector, such as the Gal4 DB- (DNA-binding domain) vector.
- a suitable vector such as the Gal4 DB- (DNA-binding domain) vector.
- the yeast strain, such as YPB2 or MaV203, harboring the construct may be transformed using the library DNA.
- a total of 1.8 X 10 7 transformants were subjected to two-hybrid selection on supplemented synthetic dextrose medium lacking leucine, tryptophan and histidine but containing 5 mM 3-amino-l,2,4-triazole.
- the selected colonies were assayed for ⁇ -galactosidase activity using standard methods.
- DNAs were isolated from positive clones and used to transform E. coli. Clones harboring the TA-fusion cDNAs were identified by PCR and plasmids were then isolated for DNA sequencing (Wang et al., 1997).
- Interactions in the yeast two-hybrid system may, for example, be analyzed by either filter assay (Chevray and Nathans, 1992) using X-gal as the substrate or by a quantification assay using ONPG (ortho-nitrophenyl-beta-D-galactoside) as the substrate (Reynolds and Lundlad, 1994). Three or more independent transformants may be used for each interaction.
- Standard methods are available for the preparation of constructs for use in identifying and characterizing CDK inhibitors useful in various embodiments of the invention.
- General molecular techniques may for example be performed by procedures generally described by Ausubel et al. (1995). Alternative equivalent methods or variations thereof may be used in accordance with the general knowledge of those skilled in this art.
- the AP3 promoter was cloned by the polymerase chain reaction
- PCR from Arabidopsis thaliana "Columbia” genomic DNA, on the basis of the published sequence (Irish and Yamamoto, 1995; GenBank Accession U30729).
- the promoter was cloned in a modified binary vector pBI121 (Clontech).
- ICKl cDNA S ⁇ Q ID NO: 1; Wang et al., 1997) was similarly amplified by PCR and transcriptionally fused with the AP3 promoter and the chimeric gene ends with a nopaline synthase terminator.
- ICKl nucleotide sequence used in AP3-ICK1 fusion was used in fusion with a Brassica rapa (B. campestris) anther-specific promoter Bgpl (Xu et al. 1993; GenBank Accession X68210).
- the Bgpl promoter has been shown to be able to direct a high level of GUS (beta-glucuronidase) gene expression in the pollen and tapetum of transgenic Arabidopsis plants (Xu et al., 1993).
- GUS beta-glucuronidase
- the resulting plasmids were introduced into Agrobacterium tumefaciens strain GV3101 (bearing helper plasmid pMP90; Koncz and Schell 1986).
- plant cells may be transformed with heterologous nucleic acids.
- heterologous denotes any nucleic acid that is introduced by transformation. Transformation techniques that may be employed include plant cell membrane disruption by electroporation, microinjection and polyethylene glycol based transformation (such as are disclosed in Paszkowski et al. EMBO J. 3:2717 (1984); Fromm et al, Proc. Natl. Acad. Sci. USA 82:5824 (1985); Rogers et al, Methods Enzymol. 118:627 (1986); and in U.S. Patent Nos.
- Transformed plant cells may be cultured to regenerate whole plants having the transformed genotype and displaying a desired phenotype, as for example modified by the expression of a heterologous CDK inhibitor during growth or development.
- a variety of plant culture techniques may be used to regenerate whole plants, such as are described in Gamborg and Phillips, "Plant Cell, Tissue and Organ Culture, Fundamental Methods", Springer Berlin, 1995); Evans et al. "Protoplasts Isolation and Culture", Handbook of Plant Cell Culture, Macmillian Publishing Company, New York, 1983; or Binding, "Regeneration of Plants, Plant Protoplasts", CRC Press, Boca Raton, 1985; or in Klee et al, Ann. Rev. of Plant Phys. 38:467 (1987).
- Standard techniques may be used for plant transformation, such as transformation of Arabidopsis.
- the AP3-ICK1 and Bgpl-ICKl constructs were tested in A. thaliana by inplanta transformation techniques. Wild type (WT) A. thaliana seeds of ecotype "Columbia” were planted in 4" pots containing soil and plants grown in a controlled growth chamber or greenhouse. The vacuum infiltration method of in planta transformation (Bechtold et al., 1993) was used to transform thaliana plants with overnight culture of A. tumefacian strain GV3101 bearing both the helper nopoline plasmid and the binary construct containing the described chimeric gene.
- pMP90 is a disarmed Ti plasmid with intact vir region acting in trans, gentamycin and kanamycin selection markers as described in Koncz and Schell (1986). Following infiltration, plants were grown to maturity and seeds (Tl) were collected from each pod individually. Seeds were surface-sterilized and screened on selective medium containing 50 mg/L kanamycin with or without 200-300 mg/L timentin. After about four weeks on selection medium, the non-transformed seedlings died. The transformed seedlings were transferred to soil in pots. Leaf DNA was isolated (Edwards et al., 1991) and analyzed by PCR for the presence of the DNA insertion.
- Alternative embodiments of the invention may make use of techniques for transformation of Brassica. Such as transformation of B. napus cv. Westar and B. carinata cv. Dodolla by co-cultivation of cotyledonary petioles or hypocotyl explants with A. tumefaciens bearing the plasmids described herein. Transformation of B. napus plants may, for example, be performed according to the method by Moloney et al. (1989). Modifications of that method may include the introduction of a 7-day explant-recovery period following co- cultivation, on MS medium with the hormone benzyladenine (BA), and the antibiotic timentin for the elimination of Agrobacterium. Transformation of B.
- BA hormone benzyladenine
- carinata plants may be performed according to the method by Babic et al. (1998).
- Cotyledonary petiole explants may be dipped in suspension of Agrobacterium bearing the desired constructs and placed on 7-cm filter paper (Whatman no. 1) on top of the regeneration medium for 2 days. After co- cultivation, explants may be transferred onto the selection medium containing 50 mg/L kanamycin. Regenerated green shoots may first be transferred to a medium to allow elongation and then to a rooting medium all containing 50 mg/L kanamycin. Putative transformants with roots (TO) may be transferred to soil. Genomic DNA may be isolated from developing leaves for PCR and Southern analyses. Seeds (Tl) from transgenic plants may then be harvested.
- Transgenic plants may be observed and characterized for alteration of traits such as petals, male sterility and ability to set seeds.
- traits such as petals, male sterility and ability to set seeds.
- flowers at different stages of development may be dissected and examined under a stereomicroscope.
- Floral samples may also be examined using scanning electron microscope for more defined morphology of floral organ meristems and their development.
- Genomic clones of sequences encoding putative CDK inhibitors may be cloned using standard techniques.
- genomic DNA may be isolated from two-week old A. thaliana seedlings (according to the procedure described by Lohdi et al., 1994).
- the genomic sequence spanning the ICKl cDNA sequence (SEQ ID NO: 1) was amplified by 30 cycles of PCR using sequence-specific primers with incorporated restriction sites.
- Pfu DNA polymerase (Stratagene), which has a higher replication fidelity than the Taq DNA polymerase, may be used.
- the amplified DNA fragment may be cloned into a suitable vector, such as pGEM5Zf(+) (Promega). Plasmids may then be purified and sequenced.
- an ICKl cDNA isolated from the two hybrid screening was cloned in frame into pBI786, a modified His 6 -tagged vector derived from pRSETB (Invitrogen) (Wang et al., 1997).
- Recombinant His 6 -ICK1 was purified from E. coli using Ni-NTA agarose resin (QIAGEN) according to manufacturer's instructions except that the final washing was with buffer D, pH 6.0 and the protein was eluted with 2 ml buffer D, pH 4.0.
- the eluent was renatured by diluting with 10X volume of a renaturing buffer (10 mM Tris pH 7.5, 500 mM NaCl, 400 mM arginine HCl, 20 ⁇ M MgCl 2 , 20 ⁇ M ZnAc and 0.1 % Tween 20) and dialysed in the same buffer (500 ml per 2 ml sample) at 4°C overnight.
- the protein samples may be concentrated with Filtron 10K concentrators.
- the sample was then dialyzed at 4°C for 3 h against 1000 volumes of the kinase assay buffer (see below) containing 0.4 mM DTT and each (0.4 ⁇ g/ml) of the protease inhibitors soybean trypsin inhibitor, antipain and apotinin.
- the protein was stored at -80 °C.
- kinases may be purified from A. thaliana tissues or cultured B. napus cells. Plant materials may be homogenized in 2 mis per gram tissue of ice cold extraction buffer consisting of 25 mM Tris pH 8.0, 100 mM NaCl, 10 mM DTT, 5 mM NaF, 1 mM Na 3 VO 4 , 1 mM ⁇ -glycerophosphate, 2.5 mM EDTA, 400 ⁇ g/ml AEBSF [4-(2-aminoethyl)-enzensulfonyl fluoride], 1 ⁇ g/ml leupeptin and 1 ⁇ g/ml pepstatin. The homogenate was centrifuged at 12,000g at 4°C for 30 min. The supernatants may be used to purify Cdc2-like protein kinases using pl
- the required amount of supernatant (150 ⁇ g protein for each reaction) was added to the beads and tumbled at 4°C for 2 h.
- the beads may be washed twice in a washing buffer consisting of 50 mM Tris pH 7.4, 250 mM NaCl, 0.1% NP-40, 2.5 mM EDTA, 1 mM DTT and inhibitor cocktail of (in final concentrations) 10 ⁇ g/ml apotinin, 10 ⁇ g/ml antipain, 10 ⁇ g/ml soybean trypsin inhibitor, 10 mM ⁇ -glycerophosphate, 1 mM NaF and 0.2 mM Na 3 VO 4 .
- Beads may then be washed twice in the kinase assay buffer (50 mM Tris pH 7.4, 10 mM MgCl, 2 mM EGTA, 2 mM DTT and the inhibitor cocktail).
- the recombinant protein was added to the reactions and incubated (tumbling slowly) for 1.5 h at 4°C.
- the kinase reaction was initiated by adding 1 ⁇ g/ ⁇ l histone HI (Sigma), 25 ⁇ M ATP and 0.05 ⁇ Ci/ul 32 P- ⁇ -ATP (final concentrations), and stopped after 20 min incubation by adding the sample buffer. Denatured supernatant was resolved by SDS- PAGE.
- RNA isolation and northern blotting analysis may be useful in various embodiments of the invention.
- various tissues may be taken from Arabidopsis plants.
- To analyse the effects of ABA and low temperature, seedlings may be treated as described (Wang et al., 1995). Briefly, seedlings (12 days) grown in pots may be cleared of soil with water, then floated in 0.1X strength MS medium without sucrose and hormones. Low temperature treatment was at 5°C for 24 h. ABA treatment was carried out in a solution containing 50 ⁇ M ABA. Seedling samples may be removed after various treatment times. Total RNA was isolated using TRIzol reagent (GIBCO BRL).
- RNA was fractionated in a 1.2% agarose gel and transferred onto Hybond-N+ nylon membrane (Amersham).
- the RNA was crosslinked to the membrane by UN-light (Stratalinker, Stratagene) and hybridized with 32 P-labeled probes.
- the membranes may be wrapped and used to expose Hyperfilm MP (Amersham) film.
- Membranes may be stripped by treating with a boiling solution of 0. IX SSC and 0.1% SDS for 5 min. Quantification of hybridized signal was performed using Molecular Dynamics Phosphorlmager and the accompanying software.
- In vitro binding assays may be useful in various aspects of the invention, for example to assay the interaction of a CDK inhibitor, or fragments of a CDK inhibitor, and a particular kinase.
- 35 S-Met labeled Cdc2a, CycD3 and ATMPK2 proteins may be expressed from a T7 promoter construct using an in vitro coupled rabbit reticulocyte transcription/translation system ('T ⁇ T', Promega).
- ⁇ i + - ⁇ TA beads Qiagen
- NNN EDTA
- Equilibrated beads may be incubated with His 6 -ICK1 (5 ⁇ g for each 10 ⁇ l beads) in 1 ml of NTN buffer for 2 h with tumbling at 10°C followed by washing with 2 X 1 ml NTN buffer. Binding experiments may be carried out in a total volume of 100 ⁇ l NTN containing 10 ⁇ l beads, plus 5 ⁇ l 35 S-Met labeled protein. The binding reaction was incubated at 10°C for 2 h, followed by washing with 3 X 0.5 ml NTN buffer. Washed beads may be eluted with 10 ⁇ l SDS-containing denaturing buffer at 100°C for 5 min, and bound 35 S-Met labeled proteins analyzed by SDS-PAGE. Gels may be imbibed with a fluorography enhancer ('Amplify', Amersham) prior to drying and exposure to X-ray film.
- a fluorography enhancer 'Amplify', Amersham
- Deletion constructs may be useful for domain mapping to determine the functional domains of a CDK inhibitor.
- N-terminal deletion constructs of ICKl were made using cDNAs with deletions of various lengths from the N-terminal end.
- the C-terminal deletion constructs were prepared by PCR using Pfu DNA polymerase with sequence-specific primers and the resulting DNA fragments were cloned into the yeast two-hybrid vector pBI771 (Kohalmi et al., 1997).
- the deletion clones may be verified by DNA sequencing.
- the constructs may be used to transform a suitable yeast strain.
- yeast strain YPB2 harboring either cdc2a or CycD3 cloned in the BD- (binding domain) vector was transformed with deletion constructs. Interactions in the yeast two-hybrid system may then, for example, be analyzed by X-gal filter assay (Chevray and Nathans, 1992) and by liquid culture assays for relative ⁇ -galactosidase activity (for example using the modified procedure of Reynolds and Lundlad, 1994). Three or more independent transformants may be used for each interaction.
- Sequence analyses including determination of sequence homology, may be performed using a variety of software, such as LASERGENE (DNASTAR). Database searches may also use a variety of software tools, such as the BLAST program (NCBI).
- the yeast two- hybrid system (Fields and Song, 1989; Kohalmi et al., 1997) may be used to identify genes, such as ICKl, that encode inhibitor proteins able to interact with the plant cyclin-dependent kinases, such as Cdc2 kinase, for use in the present invention.
- genes such as ICKl
- Cdc2 kinase the plant cyclin-dependent kinases
- 55 represented various lengths of ICKl, 7 of ICK2 and 6 of ICK3.
- a contig sequence for homologous clones disclosed by the yeast two hybrid assay may be used, as was the contig sequence for ICKl cDNA (Wang et al., 1997), to search cDNA and genomic databases at sites such as NCBI (http://www.ncbi.nlm.nih.gov) and AtDB (http://genome-www.stanford.edu/Arabidopsis), for sequences homologous to those identified by the two-hybrid screen.
- NCBI http://www.ncbi.nlm.nih.gov
- AtDB http://genome-www.stanford.edu/Arabidopsis
- Specific PCR primers may be synthesized and used to clone the genomic sequence spanning the entire coding region of a CDK inhibitor gene.
- ICKl three independent clones harboring the genomic sequence were identified in this way, sequenced and found to be identical. Alignment of ICKl genomic sequence with the ICKl cDNA sequence (SEQ ID NO: 1 ; GenBank U94772, Wang et al., 1997) reveals three introns.
- the genomic sequence in the exon regions is identical to the contig of cDNA clones except at nucleotide position 318, which is a T instead of a G as in the reported cDNA sequence (Wang et al., 1997; a majority of the cDNA clones had a G, while other clones had a T at this position).
- the existence of a T at this position in genomic DNA was verified by sequencing additional genomic clones.
- the longest open reading frame in the ICKl cDNA sequence (SEQ ID NO: 1) predicts a polypeptide of 191 amino acids (SEQ ID NO: 2; Wang et al., 1997).
- an in-frame translation termination codon was found 30 nucleotides down stream of the predicted termination codon.
- CDK inhibitor in vitro assays may be used to demonstrate that a recombinant putative CDK inhibitor, such as ICKl protein, is an effective inhibitor of plant Cdc2-like kinases. Plant CDK inhibitors may not inhibit CDK from mammalian and yeast cells (Wang et al., 1997).
- recombinant ICKl is effective in vitro in inhibiting the histone HI kinase activity of pl3 sucl -associated kinases from cultured cells of heterologous Brassica napus. In addition, it also inhibits the activity of such kinases from A. thaliana seedlings, leaves and floral tissues in vitro.
- CDK inhibitors The expression of a CDK inhibitor in particular plant tissues may be assayed to determine, for example, whether that CDK inhibitor will have utility as a division or growth modulator when expressed in such tissues.
- the expression of ICKl was analyzed in several different plant tissues. In general, the transcript abundance of ICKl was relatively low and showed low degrees of variation compared with the housekeeping genes such as TUA4 (a tubulin- gene) and GAPDH (glyceraldehyde phosphate dehydrogenase) of A. thaliana. When leaves from plants of different ages were compared, the ICKl level in sample L5 (for leaves of 5-week plants) was slightly higher. To verify the functional role of a putative CDK inhibitor in such tissues, the CDK activity may also be assayed.
- Putative CDK inhibitors may be assayed for suitable CDK inhibitor activity for use in the methods of the invention by a variety of tests. For example, induction of expression of the putative CDK inhibitor gene by abscisic acid (ABA) , a phytohormone known to inhibit plant growth (Evans, 1984), and at low temperatures.
- ABA abscisic acid
- ICKl a phytohormone known to inhibit plant growth
- ICKl a phytohormone known to inhibit plant growth
- expression of the putative CDK inhibitor gene, such as ICKl, in seedlings, such as A. thaliana seedlings may be analyzed in response to treatments with ABA.
- ICKl data from an example assay showed that after 24 h, ABA and low temperature treatments increased ICKl transcript levels to about 3 times that of the control (no ABA and at 22°C) in 2-week seedlings.
- the expression of the putative CDK inhibitor gene may be quantified.
- ICKl a correlation coefficient was obtained for the relationship of cdc2a level, ICKl level and cdc2alICKl ratio with the Cdc2-like kinase activity.
- the level of cdc2 'a expression was correlated with the level of Cdc2-like histone HI kinase activity.
- the level of ICKl expression exhibited a weak negative correlation with kinase activity.
- CDK inhibitors for use in various aspects of the invention may be identified using a yeast two hybrid screening protocol with a variety of bait fusion protein sequences.
- ICKl was independently cloned in a screen using A. thaliana CycD3 as the bait, indicating that ICKl interacts with CycD3 in the two hybrid assay.
- further binding assays may be conducted. For example, to test the interactions of ICKl, cdc2a and CycD3 cDNAs were transcribed and translated in an in vitro system.
- Cdc2a and CycD3 proteins were incubated with recombinant His 6 - ICK1 protein expressed in E. coli.
- Cdc2a and CycD3 bound to Ni-NTA beads only after they were incubated with recombinant ICKl.
- the amount of CycD3 bound to recombinant ICKl protein was more than the control protein ATMPK2 which showed little binding despite the much higher input used.
- the regions of a CDK inhibitor that are functionally involved in interactions with other proteins may be mapped by deletion mapping using a variety of techniques, such as the yeast two-hybrid system and variations thereof. Such in vitro assay results may be verified by in vivo tests, since the persistence of interactions in the two hybrid system may be affected by possible alterations in functionality of plant proteins expressed in yeast. As an example of an in vitro assay, to determine the functional significance of the C-terminal domain and other regions of ICKl, three N-terminal and three C-terminal deletion mutants were assessed for their interactions with Cdc2a and CycD3 in the two-hybrid system.
- ⁇ -galactosidase marker gene activation in the two hybrid system was stronger for the interaction of all ICKl constructs with CycD3 compared to Cdc2a, indicative of a stronger or more persistent interaction between ICKl and CycD3 in the two-hybrid system.
- Major shifts in ⁇ - galactosidase activity were observed when amino acid regions 3-72, 109-153 and 176-191 were deleted. An increase in activity was observed upon deletion of amino acids 3-72.
- the functional importance of a portion of a CDK inhibitor may also be assayed by analyzing the portion of cDNA required for the recovery of clones by each bait construct in the two hybrid system. For example, the region spanning amino acids 109-153 of ICKl for its interaction with CycD3 was supported by the analysis of the minimum cDNA length required for the recovery of clones by each bait construct. With CycD3 as the bait, the shortest ICKl cDNA was N-terminal deleted for amino acids 1-129, while with Cdc2a, seven clones with further deletions extending to amino acid 154 were also isolated. Thus, deletions extending beyond amino acid 130 rendered these clones unrecoverable by the two-hybrid screening using CycD3 as the bait.
- One aspect of the invention utilizes functionally important regions of a CDK inhibitor, such as ICKl, as components of novel CDK inhibitors.
- the functionally important regions of a CDK inhibitor may be determined through routine assays. Alternatively, randomly selected portions of a CDK inhibitor may be selected for use in routine assays to determine whether the selected region is capable of functioning as a CDK inhibitor in the context of the present invention.
- regions of ICKl may be used, such as the 109-153 region and/or the 163-191 region, with or without additional regions from ICKl or other CDK inhibitors, provided the recombinant protein meets the functional requirements of the present invention (which may be determined through routine screening of functionality).
- Arabidopsis transformation with ICKl constructs A wide variety of transformation techniques may be used in accordance with the invention to introduce CDK inhibitor genes into plants.
- the invention provides methods of assaying heterologous CDK inhibitor function in a model plant, such as Arabidopsis.
- transformation may be caried out by infiltration.
- seeds (Tl generation) collected from infiltrated Arabidopsis plants may be surface-sterilized and placed onto MS medium containing 50 ⁇ g/ml kanamycin.
- the antibiotic timentin may also be included in the medium to prevent any bacterial growth, which could occur due to carrier-over from the infiltration.
- transformants may be transferred to soil in pots.
- the presence of the DNA insertion was confirmed by extracting the genomic DNA and then using it for PCR amplification.
- the non-transformed wild-type plant gave a negative signal, all twelve (12) plants selected for their resistance to kanamycin were positive for transforming DNA.
- AP3-ICK1 chimeric gene on petal and stamen development Various aspects of the invention may be used to obtain a wide variety of phenotypic variations in plant mo ⁇ hology or other characteristics.
- transformed A. thaliana plants carrying the AP3-ICK1 construct displayed a range of phenotypes with regard to petal and stamen mo ⁇ hology (Table 1).
- Such variation may be due to the insertion in alternative embodiments of the invention of the CDK inhibitor gene into different sites of the plant genome.
- the plants may be classed into three groups: (1) no visible petals, (2) visible petals but reduced size and (3) visible petals with no apparent difference to those of non-transformed plants (Table 1).
- transgenic plants with male sterility may set seeds after pollination, using pollen from non-transformed plants, indicating that the female reproduction system is unaffected in these male sterile plants. Apart from these specific modifications, these transgenic plants otherwise grew and developed normally.
- Table 1 Summary of phenotypes of A. thaliana plants transformed with AP3-ICK1 chimeric gene.
- T2 plants may be studied to determine the segregation of the inserted gene and also to verify whether the particular phenotype is co-inherited with the inserted gene.
- T2 seeds of ICKl transformants were sterilized and placed onto the selective medium.
- T2 seeds of one transformant (#2) showed 1 : 1 ratio of segregation between resistant (99) versus non-resistant (102) seedlings.
- transformant #2 was male sterile, the T2 seeds were obtained by crosses using wild type pollen. This ratio indicates that there is one insertion in the genome of this transformant.
- T2 plants displayed the same phenotype as the corresponding Tl plants.
- RNA blotting and hybridization were performed as described above.
- Expression of ICKl can be directed to more differentiated cells such as pollen, to determine its effect on differentiated cells to compare the effect on cells in proliferative tissue such as stamen primordia.
- transgenic plants were obtained using Bgpl-ICKl chimeric gene construct. Eighteen (18) such transgenic Arabidopsis plants were transferred to soil and grew to maturity. All showed normal development of flower and anthers, unlike transgenic plants with AP3-ICK1 construct most of which showed petal alteration and male sterility. The Bgpl-ICKl plants all set seeds without artificial pollination.
- transgenic Arabidopsis plants As Bgpl promoter has been shown to be able to direct a high level of GUS (beta-glucuronidase) gene expression in the pollen and tapetum of transgenic Arabidopsis plants (Xu et al., 1993), the observation that no significant male sterility phenotype developed in transgenic Bgpl-ICKl plants indicates that a differentiated cell such as pollen can tolerate a moderate level of ICKl with no detrimental effect on its function.
- GUS beta-glucuronidase
- the transgenic Brassica phenotypes were consistent with the pattern of AP3 promoter-directed gene expression, i.e. stronger expression in petal and stamen primordia and possibly low levels of expression in the inner integument or ovule (Day et al., 1995). Of fifty-two primary transformants, four showed altered petal development while other transformed plants showed normal petal development and seed-setting. For plants showing poor seed-setting, seeds were obtained by crosses with non-transformed wild-type B. napus plants. The inheritance of the altered phenotype was evident in progeny plants.
- transgenic B. napus plants were obtained with a chimeric gene construct consisting of the Bgpl promoter and ICKl. Of over forty putative transformants obtained, four showed reduced seed setting. The degree of reduction varied from an amount of about half the seed-setting in normal plants (in term of number of seeds per pods) to nearly complete sterility.
- Northern blot analysis showed a strong expression of ICKl in the anther of a transgenic plant with male sterile phenotype (see below), suggesting that although moderate to low levels of expression did not affect the fertility, a higher level of expression could result in a sterile phenotype. It is also noted that none of the 18 Arabidopsis transformants showed any sterile phenotype with this construct.
- the Bgpl promoter which is from B. rapa (B. campestris) (Xu et al., 1993), may be more effective in activating transgenic ICKl expression in B. napus than in A. thaliana plants.
- Brassica are indicative of the fact that it may be desirable in alternative embodiments to select promoters that mediate very strong expression of the CDK inhibitor gene, such as ICKl, during pollen/anther development, in order to optimize the occurrence of sterility.
- ICKl in transgenic B. napus plants was analysed by northern hybridization using 32 P-labeled ICKl cDNA as probe.
- the Bpgl promoter has previously been shown to direct strong exogenous GUS reporter gene expression in pollen of A. thaliana and Nicotiana tobacum (Xu et al., 1993).
- This example illustrates expression analysis for transgenic B. napus plants harboring Bgpl-ICKl constructs.
- RNA samples were isolated from the leaf and mature anthers of a transgenic plant showing sterility phenotype (significant reduction in seed-setting) and a control B. napus Westar plant. For each sample, 15 ⁇ g of RNA was loaded and separated by electrophoresis. RNA transfer and hybridization were performed as described.
- ICKl expression was analysed in plants transformed by AP3- ICK1 construct.
- One B. napus plant showed changes in petal development including absence of one to all four petals and smaller petals.
- RNA samples were isolated from the leaf, sepal, petal, anther and whole young flower of the transgenic plant and the control plant. The only significant ICKl expression was shown to be in the petals of the transgenic plants. There was no detectable signal under the conditions used for the tissues from the control plant.
- ICKl expression was due to over- expression of ICKl in petals.
- other plant CDK inhibitors may be used in transgenic or transient expression for regulating plant or plant cell growth and development. An example is described here.
- a cDNA clone CDKIl (AJ002173, SEQ ID No. 15 and SEQ ID No.16) sharing some sequence similarity with ICKl , ICK2, ICN2, ICN6 and ICN7 (Table 2) was identified from Chenopodium rubrum (by Fountain, Renz and Beck, with information available through NCBI databases at http://www.ncbi.nih.gov). C. rubrum seeds were collected in Saskatchewan, Canada. RNA was isolated from seedlings and leaves. The full-length coding region of CDKIl cDNA was cloned using RNA RT-PCR. The amplified fragment was cloned in sense orientation with a constitutive promoter and sequenced.
- the sequence data showed that the cloned cDNA was identical to CDKIl of C. rubrum in the database.
- the Agrobacterium strain harboring an expression construct of CDKIl was used to transform Arabidopsis. Selection for transformants was performed as described elsewhere herein. Significant mo ⁇ hological changes in plant development were observed in over one third of 38 transformants. These results indicate that the expression of C. rubrum CDKIl may modify the growth and development of Arabidopsis thaliana. Chenopodium and Arabidopsis are phylogenetically rather distant species with Chenopodium belonging to the subclass of Caryophyllidae and Arabidopsis to the subclass Dilleniidae.
- a Chenopodium CDK inhibitor functions in Arabidopsis in the context of the present invention indicates that diverse plant CDK inhibitors may be used in various aspects of the present invention.
- ICN2 has been used to transform A. thaliana to modify growth and development of that plant, producing transformed plants with distinct phenotypes.
- diverse CDK inhibitors may be used in accordance with various aspects of the invention.
- CDK inhibitors may be used in various aspects of the invention to interact with a variety of regulatory components, such as other cell cycle proteins. For example, in some embodiments, it may be desirable to target a known regulatory moity with a CDK inhibitor. Accordingly, in one aspect of the invention, an assay is provided to determine if a CDK inhibitor interacts with a known protein. Such interactions may be analyzed by a variety of assays for protein-protein interactions including the yeast two-hybrid assay (e.g. Phizicky and Fields, 1995; Malmqvist and Karlsson, 1997).
- the full-length cDNA of the gene to be analyzed may be cloned in a GAL4-binding domain vector (Kohalmi et al, 1997) using PCR and gene specific primers with flanking restriction sites.
- Such constructs may be used to transform the yeast carrying the CDK inhibitor of interest, such as ICKl in a GAL4-activation domain vector.
- the interactions of ICKl with a number of cell cycle-related genes from A. thaliana were examined in accordance with the invention (Table 3).
- the yeast two-hybrid assay results indicate that in particular embodiments of the invention, ICKl protein may interact with Cdc2a but not with Cdc2b.
- ICKl may interact with D- class cyclins, CycDl, CycD2 and CycD3, while not interacting with A/B-class mitotic cyclins, CycA2, CycBl and CycB2 (Table 3).
- the yeast two-hybrid assay results also indicate that ICKl may not interact in some embodiments with PCNA, also a cell cycle protein, and ATMAP2, a kinase sharing some similarity with Cdc2 kinase.
- CDK inhibitors Other plant CDK inhibitors and CDK inhibitor genes sharing functional and sequence similarity with ICKl may be identified using an approach similar to the approach used to isolate ICKl, based for example on their interactions with either Arabidospis Cdc2a or a D-class cyclin (e.g. cyclin D3 or cyclin D2).
- the CDK inhibitors identified in screens using Cdc2a are designated herein as ICKs (for ihteractors of Cdc2 i ⁇ nase) and those identified in screens using cyclins are designated ICNs (for ihteractors of Cycli «).
- Some CDK inhibitors may be isolated independently from both types of screens.
- ICK2 SEQ ID NO: 6
- ICN2 SEQ ID NO: 7
- ICN6 SEQ ID NO: 8
- ICN7 SEQ ID NO: 9
- these ICK/ICN proteins all share some sequence similarity in the region of ICKl that is functionally important in some embodiments for its interaction with Cdc2a and cyclin D3 (discussed above in the section on "domains for ICKl interactions with Cdc2a and cyclin D3").
- These homologous genes or proteins may be used in some embodiments, in a manner similar to ICKl , to modulate plant growth and development.
- One or more such genes or proteins may be used in some embodiments alone or in combination to provide temporal and spatial regulation of cell cycle initiation and progressing during plant development in accordance with this invention.
- Cdk-interating protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase 5 holoenzyme.
- Plant Cyclins a unified nomenclature for plant A-, B- and D-type cyclins based on sequence organization. Plant Mol Biol 32 : 1003- 1018
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41269/99A AU762816B2 (en) | 1998-06-08 | 1999-06-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
EP99924620A EP1086226A1 (en) | 1998-06-08 | 1999-06-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
CA2329684A CA2329684C (en) | 1998-06-08 | 1999-06-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
US09/733,507 US7078591B2 (en) | 1998-06-08 | 2000-12-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
US11/456,843 US7732663B2 (en) | 1998-06-08 | 2006-07-11 | Cyclin-dependent kinase inhibitors as plant growth regulators |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002235978A CA2235978A1 (en) | 1998-06-08 | 1998-06-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
CA2,235,978 | 1998-06-08 | ||
CA002256121A CA2256121A1 (en) | 1998-06-08 | 1998-12-31 | Cyclin-dependent kinase inhibitors as plant growth regulators |
CA2,256,121 | 1998-12-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/733,507 Continuation-In-Part US7078591B2 (en) | 1998-06-08 | 2000-12-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999064599A1 true WO1999064599A1 (en) | 1999-12-16 |
Family
ID=25680171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000532 WO1999064599A1 (en) | 1998-06-08 | 1999-06-08 | Cyclin-dependent kinase inhibitors as plant growth regulators |
Country Status (5)
Country | Link |
---|---|
US (3) | US7078591B2 (en) |
EP (1) | EP1086226A1 (en) |
AU (1) | AU762816B2 (en) |
CA (1) | CA2256121A1 (en) |
WO (1) | WO1999064599A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000069883A1 (en) * | 1999-05-14 | 2000-11-23 | Fred Hutchinson Cancer Research Center | Methods for increasing plant cell proliferation by functionally inhibiting a plant cyclin inhibitor gene |
WO2002050292A2 (en) * | 2000-12-08 | 2002-06-27 | Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agrifood Canada | Modulation of plant cyclin-dependent kinase inhibitor activity |
WO2002028893A3 (en) * | 2000-07-14 | 2002-12-12 | Cropdesign Nv | Plant cyclin-dependent kinase inhibitors |
WO2001085946A3 (en) * | 2000-05-12 | 2003-03-13 | Cropdesign Nv | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
US7265267B1 (en) | 1997-09-16 | 2007-09-04 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
US7329799B2 (en) | 2003-07-14 | 2008-02-12 | Monsanto Technology Llc | Materials and methods for the modulation of cyclin-dependent kinase inhibitor-like polypeptides in maize |
EP1924136A2 (en) * | 2005-07-29 | 2008-05-28 | Targeted Growth, Inc. | Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp |
US7732663B2 (en) | 1998-06-08 | 2010-06-08 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Cyclin-dependent kinase inhibitors as plant growth regulators |
EP2194131A3 (en) * | 1997-09-16 | 2010-09-22 | CropDesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
AU2007201513B2 (en) * | 2000-05-12 | 2011-06-23 | Cropdesign N.V. | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
US9062323B2 (en) | 2011-04-11 | 2015-06-23 | The Regents Of The University Of California | Identification and use of KRP mutants in wheat |
US9556448B2 (en) | 2011-04-11 | 2017-01-31 | Targeted Growth, Inc. | Identification and the use of KRP mutants in plants |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2347410B (en) * | 1999-01-21 | 2003-08-06 | Tony Norman Marsh | Plant cell growth promotion material |
EP3377908B1 (en) | 2015-11-18 | 2020-08-05 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026327A1 (en) * | 1996-01-18 | 1997-07-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
WO1999014331A2 (en) * | 1997-09-16 | 1999-03-25 | Cropdesign Nv | Cyclin-dependent kinase inhibitors and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8200523A (en) * | 1982-02-11 | 1983-09-01 | Univ Leiden | METHOD FOR TRANSFORMING IN VITRO PLANT PROTOPLASTS WITH PLASMIDE DNA. |
NL8300698A (en) * | 1983-02-24 | 1984-09-17 | Univ Leiden | METHOD FOR BUILDING FOREIGN DNA INTO THE NAME OF DIABIC LOBAL PLANTS; AGROBACTERIUM TUMEFACIENS BACTERIA AND METHOD FOR PRODUCTION THEREOF; PLANTS AND PLANT CELLS WITH CHANGED GENETIC PROPERTIES; PROCESS FOR PREPARING CHEMICAL AND / OR PHARMACEUTICAL PRODUCTS. |
US5231019A (en) * | 1984-05-11 | 1993-07-27 | Ciba-Geigy Corporation | Transformation of hereditary material of plants |
US4743548A (en) * | 1984-09-25 | 1988-05-10 | Calgene, Inc. | Plant cell microinjection technique |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4943674A (en) * | 1987-05-26 | 1990-07-24 | Calgene, Inc. | Fruit specific transcriptional factors |
NZ221259A (en) | 1986-07-31 | 1990-05-28 | Calgene Inc | Seed specific transcriptional regulation |
US4801540A (en) * | 1986-10-17 | 1989-01-31 | Calgene, Inc. | PG gene and its use in plants |
US5015580A (en) * | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
NZ224787A (en) | 1987-05-26 | 1990-08-28 | Calgene Inc | A dna construct for specifically modifying the phenotype of fruit as distinct from other plant tissue |
WO1991001324A1 (en) | 1989-07-19 | 1991-02-07 | Calgene, Inc. | Ovary-tissue transcriptional factors |
WO1991001373A1 (en) | 1989-07-19 | 1991-02-07 | Calgene, Inc. | Fruit-specific transcriptional factors |
US5175095A (en) * | 1989-07-19 | 1992-12-29 | Calgene, Inc. | Ovary-tissue transcriptional factors |
US5283173A (en) * | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
ATE205530T1 (en) | 1990-03-16 | 2001-09-15 | Calgene Llc | NEW SEQUENCES PREFERABLY EXPRESSED DURING EARLY GERM DEVELOPMENT AND RELATED METHODS |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
DE69133537T2 (en) * | 1990-11-29 | 2007-05-31 | Cropdesign N.V. | CONTROL OF PLANT CELL REPRODUCTION AND GROWTH |
ATE316573T1 (en) * | 1992-10-30 | 2006-02-15 | Gen Hospital Corp | INTERACTING TRAP SYSTEM FOR ISOLATION OF PROTEINS |
CA2166380A1 (en) * | 1993-06-30 | 1995-01-12 | Sandra G. Fitzpatrick-Mcelligott | Method for introducing a biological substance into a target |
US5723765A (en) * | 1994-08-01 | 1998-03-03 | Delta And Pine Land Co. | Control of plant gene expression |
BR9807886A (en) | 1997-03-26 | 2000-02-22 | Univ Cambridge Tech | Process for obtaining a plant with altered growth characteristics or altered architecture, chimeric gene, plant cell, plant, seed thereof, isolated DNA fragment, and uses of a protein that controls cell division, and of a DNA that encodes the same |
US5885779A (en) * | 1997-09-09 | 1999-03-23 | University Of British Columbia | Repressed trans-activator system for characterization of protein-protein interactions |
CA2256121A1 (en) | 1998-06-08 | 1999-12-08 | Hong Wang | Cyclin-dependent kinase inhibitors as plant growth regulators |
CA2367476A1 (en) | 1999-03-19 | 2000-09-28 | Cropdesign N.V. | Method for enhancing and/or improving plant growth and/or yield or modifying plant architecture |
-
1998
- 1998-12-31 CA CA002256121A patent/CA2256121A1/en not_active Abandoned
-
1999
- 1999-06-08 AU AU41269/99A patent/AU762816B2/en not_active Ceased
- 1999-06-08 WO PCT/CA1999/000532 patent/WO1999064599A1/en active IP Right Grant
- 1999-06-08 EP EP99924620A patent/EP1086226A1/en not_active Withdrawn
-
2000
- 2000-12-08 US US09/733,507 patent/US7078591B2/en not_active Expired - Fee Related
-
2001
- 2001-12-18 US US10/451,139 patent/US20040098763A1/en not_active Abandoned
-
2006
- 2006-07-11 US US11/456,843 patent/US7732663B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026327A1 (en) * | 1996-01-18 | 1997-07-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for mediating cell cycle progression |
WO1999014331A2 (en) * | 1997-09-16 | 1999-03-25 | Cropdesign Nv | Cyclin-dependent kinase inhibitors and uses thereof |
Non-Patent Citations (5)
Title |
---|
DOERNER P ET AL: "CONTROL OF ROOT GROWTH AND DEVELOPMENT BY CYCLIN EXPRESSION", NATURE, vol. 380, 11 April 1996 (1996-04-11), pages 520 - 523, XP002045509 * |
DOONAN J: "PLANT GROWTH: ROOTS IN THE CELL CYCLE", CURRENT BIOLOGY, vol. 6, no. 7, 1 July 1996 (1996-07-01), pages 788/789, XP002045511 * |
FOUNTAIN, M.D.: "Chenopodium rubrum G1 cyclin-dependent kinase inhibitor mRNA, complete cds", EMBL ACCESSION NO. AJ002173, 27 November 1997 (1997-11-27), XP002067552 * |
WANG, H., ET AL.: "A plant cyclin-dependent kinase inhibitor gene", NATURE, vol. 386, 3 April 1997 (1997-04-03), pages 451 - 452, XP002054969 * |
WANG, H., ET AL.: "Arabidopsis thaliana cyclin-dependent kinase inhibitor protein (ICK1) mRNA, complete cds.", EMBL ACCESSION NO. U94772, 29 April 1997 (1997-04-29), XP002067455 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2194131A3 (en) * | 1997-09-16 | 2010-09-22 | CropDesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
US7265267B1 (en) | 1997-09-16 | 2007-09-04 | Cropdesign N.V. | Cyclin-dependent kinase inhibitors and uses thereof |
US7732663B2 (en) | 1998-06-08 | 2010-06-08 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Cyclin-dependent kinase inhibitors as plant growth regulators |
US7230089B1 (en) | 1999-05-14 | 2007-06-12 | Fred Hutchinson Cancer Research Center | Methods for increasing plant cell proliferation by functionally inhibiting a plant cyclin inhibitor gene |
WO2000069883A1 (en) * | 1999-05-14 | 2000-11-23 | Fred Hutchinson Cancer Research Center | Methods for increasing plant cell proliferation by functionally inhibiting a plant cyclin inhibitor gene |
AU2007201513B2 (en) * | 2000-05-12 | 2011-06-23 | Cropdesign N.V. | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
WO2001085946A3 (en) * | 2000-05-12 | 2003-03-13 | Cropdesign Nv | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
AU2007201513C1 (en) * | 2000-05-12 | 2014-01-16 | Cropdesign N.V. | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
US8193414B2 (en) * | 2000-05-12 | 2012-06-05 | Cropdesign N.V. | Method for modulating plant growth, nucleic acid molecules and polypeptides encoded thereof useful as modulating agent |
AU2007201513A8 (en) * | 2000-05-12 | 2011-07-14 | Cropdesign N.V. | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
AU2007201513B8 (en) * | 2000-05-12 | 2011-07-14 | Cropdesign N.V. | Nucleic acid molecules encoding plant cell cycle proteins and uses therefor |
WO2002028893A3 (en) * | 2000-07-14 | 2002-12-12 | Cropdesign Nv | Plant cyclin-dependent kinase inhibitors |
US7807872B2 (en) | 2000-07-14 | 2010-10-05 | Cropdesign N.V. | Down regulation of plant cyclin-dependent kinase inhibitors |
WO2002050292A3 (en) * | 2000-12-08 | 2002-09-19 | Ca Minister Agriculture & Food | Modulation of plant cyclin-dependent kinase inhibitor activity |
WO2002050292A2 (en) * | 2000-12-08 | 2002-06-27 | Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agrifood Canada | Modulation of plant cyclin-dependent kinase inhibitor activity |
US7329799B2 (en) | 2003-07-14 | 2008-02-12 | Monsanto Technology Llc | Materials and methods for the modulation of cyclin-dependent kinase inhibitor-like polypeptides in maize |
EP1924136A4 (en) * | 2005-07-29 | 2009-05-13 | Targeted Growth Inc | Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp |
EP2422615A3 (en) * | 2005-07-29 | 2012-04-18 | Targeted Growth, Inc. | Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp |
JP2009502175A (en) * | 2005-07-29 | 2009-01-29 | ターゲット・グロース・インコーポレーテッド | Protection of dominant negative mutant KRP protein against inhibition of active cyclin-CDK complex by wild-type KRP |
EP1924136A2 (en) * | 2005-07-29 | 2008-05-28 | Targeted Growth, Inc. | Dominant negative mutant krp protein protection of active cyclin-cdk complex inhibition by wild-type krp |
US8742205B2 (en) | 2005-07-29 | 2014-06-03 | Targeted Growth, Inc. | Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP |
US9637754B2 (en) | 2005-07-29 | 2017-05-02 | Targeted Growth, Inc. | Dominant negative mutant KRP protein protection of active cyclin-CDK complex inhibition by wild-type KRP |
US10070601B2 (en) | 2011-04-11 | 2018-09-11 | Targeted Growth, Inc. | Identification and the use of KRP mutants in plants |
US9062323B2 (en) | 2011-04-11 | 2015-06-23 | The Regents Of The University Of California | Identification and use of KRP mutants in wheat |
US9556448B2 (en) | 2011-04-11 | 2017-01-31 | Targeted Growth, Inc. | Identification and the use of KRP mutants in plants |
US9745596B2 (en) | 2011-04-11 | 2017-08-29 | Targeted Growth, Inc. | Identification and use of KRP mutants in wheat |
Also Published As
Publication number | Publication date |
---|---|
AU4126999A (en) | 1999-12-30 |
US7078591B2 (en) | 2006-07-18 |
US20010025379A1 (en) | 2001-09-27 |
EP1086226A1 (en) | 2001-03-28 |
US20040098763A1 (en) | 2004-05-20 |
US20060253930A1 (en) | 2006-11-09 |
US7732663B2 (en) | 2010-06-08 |
CA2256121A1 (en) | 1999-12-08 |
AU762816B2 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7732663B2 (en) | Cyclin-dependent kinase inhibitors as plant growth regulators | |
AU738652B2 (en) | Genetic control of plant growth and development | |
AU723363B2 (en) | Nucleic acid encoding GAI gene of arabidopsis thaliana | |
AU717860B2 (en) | Flowering genes | |
AU782427B2 (en) | Methods and means for modification of plant flowering characteristics | |
CA2532939A1 (en) | Plant cell cycle genes and methods of use | |
JP2001519659A (en) | Plants with modified growth | |
EP0972060A1 (en) | Method and means for modulating plant cell cycle proteins and their use in plant cell growth control | |
CA2329684C (en) | Cyclin-dependent kinase inhibitors as plant growth regulators | |
AU2003204298B2 (en) | Cyclin-Dependent Kinase Inhibitors as Plant Growth Regulators | |
US20050289669A1 (en) | TTG3 deficient plants, nucleic acids, polypeptides and methods of use thereof | |
WO2002050292A2 (en) | Modulation of plant cyclin-dependent kinase inhibitor activity | |
KR100990071B1 (en) | AGB protein interacting with AIA originated from Arabidopsis thaliana | |
CA2272608A1 (en) | Gene regulating cell division cycle in plants | |
Bradley | Flowering genes | |
CA2433048A1 (en) | Modulation of plant cyclin-dependent kinase inhibitor activity | |
CA2235978A1 (en) | Cyclin-dependent kinase inhibitors as plant growth regulators | |
MXPA99008795A (en) | Plants with modified growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2329684 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09733507 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999924620 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 41269/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999924620 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 41269/99 Country of ref document: AU |